Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease
JAMA · 08.10.2026
DOI: 10.1001/jama.2026.18828 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA, online erschienen am 08.10.2026. Verfasst von Brage Brakedal und 40 weiteren Autor:innen. Beteiligte Einrichtung: Neuro-SysMed Center for Clinical Treatment Research, Department of Neurology, Haukeland University Hospital, Bergen, Norway. Hauptthemen laut MEDLINE: Niacinamide, Parkinson Disease, Pyridinium Compounds. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Nicotinamide riboside, a nicotinamide adenine dinucleotide precursor, has been proposed as a potential disease-modifying therapy for Parkinson disease based on preclinical and early studies. Whether prolonged oral nicotinamide riboside improves clinical outcomes in Parkinson disease is unknown.
Objective
To determine whether nicotinamide riboside improves clinical outcomes in Parkinson disease compared with placebo. Design, Setting, and Participants Randomized, double-blind, placebo-controlled, phase 3 clinical trial conducted at 11 centers in Norway. Eligible participants were patients aged 35 years or older with Parkinson disease diagnosed within 2 years before enrollment, Hoehn and Yahr disease stage less than 3, abnormal dopamine transporter scintigraphy findings confirming dopaminergic nigrostriatal denervation, and stable dopaminergic treatment before enrollment. Of 537 screened individuals, 410 were randomized from May 6, 2020, to June 20, 2024, and 393 were included in the primary analysis. Final follow-up was completed on June 19, 2025.
Interventions
Patients were randomized to receive oral nicotinamide riboside, 500 mg twice daily (n = 206), or matching placebo (n = 204) for 52 weeks. Main Outcomes and Measures The primary outcome was change from baseline to week 52 in the Movement Disorder Society Unified Parkinson Disease Rating Scale total score (MDS-UPDRS parts I-III; range, 0-236, with higher scores indicating more severe disease; clinically important differences for improvement and worsening, 6.7 and 5.2 points, respectively), analyzed using a mixed model for repeated measures. The 5 key secondary outcomes were the individual parts I, II, and III of the MDS-UPDRS; dopamine transporter single-photon emission computed tomography brain imaging findings; and the Non-Motor Symptoms Scale score (NMSS; range, 0-360, with higher scores indicating greater nonmotor symptom burden).
Results
Among the 393 participants in the primary analysis, the mean age was 65.6 (SD, 9.4) years and 133 (34%) were female. At week 52, the total MDS-UPDRS score increased by 2.45 (95% CI, 0.80-4.10) points with nicotinamide riboside and decreased by 0.27 (95% CI, −1.95 to 1.40) points with placebo, yielding an adjusted mean difference of 2.72 points (95% CI, 0.47-4.98 points; P = .02), favoring placebo. Of the 5 prespecified key secondary outcomes, 4 showed no significant difference, but nonmotor symptom burden worsened more with nicotinamide riboside (NMSS score adjusted mean difference, 4.22 [95% CI, 1.07-7.37] points; P = .009). Serious adverse events occurred in 17 (8.3%) of 205 participants receiving nicotinamide riboside and 29 (14.1%) of 205 receiving placebo in the safety population. Conclusions and Relevance Among patients with early Parkinson disease, nicotinamide riboside treatment for 52 weeks did not improve clinical outcomes and was associated with worse clinical outcomes than placebo. These findings do not support nicotinamide riboside as a disease-modifying treatment for Parkinson disease. Trial Registration ClinicalTrials.gov Identifier: NCT03568968
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Neuro-SysMed Center for Clinical Treatment Research, Department of Neurology, Haukeland University Hospital, Bergen, Norway.
- Department of Clinical Medicine, University of Bergen, Bergen, Norway.
- K. G. Jebsen Center for Translational Research in PD, University of Bergen, Bergen, Norway.
- Department of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany.
- Department of Neurology, Bodø Hospital, Bodø, Norway.
- Department of Radiology, Nuclear Medicine/PET Centre, Haukeland University Hospital, Bergen, Norway.
Zitieren
APA
Brakedal, B., Skeie, G. O., Derad, C., Alstadhaug, K. B., Anundskås, I., Berven, H., Biermann, M., Bjørnarå, K. A., Torres Cleuren, Y. N., Dalbro, S. E. J., Eidelberg, D., Foldnes, K., Fortes, G., Haugarvoll, K., Herlofson, K., Hustad, E., HogenEsch, R. I., Johanson, G. A. S., Johnsen, S. H., …, & Tzoulis, C. (2026). Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease. JAMA. https://doi.org/10.1001/jama.2026.18828
Vancouver
Brakedal B, Skeie GO, Derad C, Alstadhaug KB, Anundskås I, Berven H, et al. Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease. JAMA. 2026. doi:10.1001/jama.2026.18828
BibTeX
@article{Brakedal2026,
author = {Brakedal, Brage and Skeie, Geir Olve and Derad, Carlotta and Alstadhaug, Karl Bjørnar and Anundskås, Ingunn and Berven, Haakon and Biermann, Martin and Bjørnarå, Kari Anne and Torres Cleuren, Yamila N and Dalbro, Solveig E J and Eidelberg, David and Foldnes, Kjartan and Fortes, Gabriela and Haugarvoll, Kristoffer and Herlofson, Karen and Hustad, Eldbjørg and HogenEsch, Roelfien Ida and Johanson, Gard Aasmund Skulstad and Johnsen, Stein Harald and Kunszt, Krisztina and Kverneng, Simon and Labusau, Aliaksei and Lie, Ingeborg Haugesag and Lilleng, Hallvard and Lundervold, Katarina and Lundqvist, Christofer and Ma, Yilong and McCann, Adrian and Njølstad, Tormund Haugland and Pihlstrøm, Lasse and Riemer, Frank and Rognerud, Anna Kaja and Sheard, Erika and Simonsen, Axel Meyer and Storm, Eline and Svensen, Magnus and Toker, Lilah and Tunold, Jon-Anders and Dölle, Christian and Friede, Tim and Tzoulis, Charalampos},
title = {Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease},
journal = {JAMA},
year = {2026},
doi = {10.1001/jama.2026.18828}
}
EUVIMED